Literature DB >> 28700045

Chagas disease: review of needs, neglect, and obstacles to treatment access in Latin America.

Eloan Pinheiro1, Lucia Brum-Soares2, Renata Reis3, Juan-Carlos Cubides2.   

Abstract

After more than one century since its discovery, Chagas disease is still extremely prevalent in 21 Latin American countries. Chagas disease is one of the most concerning public health problems in Latin America; the overall cost of CD treatment is approximately 7 billion United States dollars per year and it has a strong social impact on populations. Little progress has been made regarding the access to diagnosis and treatment at the primary health care level, calling into question the current policies to ensure the right to health and access to essential medications. In this article, diverse dimensions of access to treatment for Chagas disease are reviewed, illustrating the present state of benznidazole medication in relation to global production capacity, costs, and needs. The findings are based on an investigation requested by Médecins Sans Frontières Brazil through a consultancy in 2015, aiming to estimate the current costs of benznidazole production.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28700045     DOI: 10.1590/0037-8682-0433-2016

Source DB:  PubMed          Journal:  Rev Soc Bras Med Trop        ISSN: 0037-8682            Impact factor:   1.581


  17 in total

1.  The CUIDA Chagas Project: towards the elimination of congenital transmission of Chagas disease in Bolivia, Brazil, Colombia, and Paraguay.

Authors:  Andréa Silvestre de Sousa; Debbie Vermeij; Gabriel Parra-Henao; Vidalia Lesmo; Evelin Fortún Fernández; José Jorge Chura Aruni; Fernanda de Souza Nogueira Sardinha Mendes; Laura C Bohorquez; Alejandro O Luquetti
Journal:  Rev Soc Bras Med Trop       Date:  2022-04-29       Impact factor: 2.141

2.  Benznidazole affects expression of Th1, Th17 and Treg cytokines during acute experimental Trypanosoma cruzi infection.

Authors:  Mariana Gatto; Larissa Ragozo Cardoso Oliveira; Fernanda De Nuzzi Dias; João Pessoa Araújo Júnior; Carlos Roberto Gonçalves Lima; Eliana Peresi Lordelo; Rodrigo Mattos Dos Santos; Cilmery Suemi Kurokawa
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2017-12-12

3.  Effects of IFN-γ coding plasmid supplementation in the immune response and protection elicited by Trypanosoma cruzi attenuated parasites.

Authors:  Cecilia Pérez Brandán; Andrea C Mesías; Cecilia Parodi; Rubén O Cimino; Carolina Pérez Brandán; Patricio Diosque; Miguel Ángel Basombrío
Journal:  BMC Infect Dis       Date:  2017-11-25       Impact factor: 3.090

4.  The economic value of identifying and treating Chagas disease patients earlier and the impact on Trypanosoma cruzi transmission.

Authors:  Sarah M Bartsch; Cameron M Avelis; Lindsey Asti; Daniel L Hertenstein; Martial Ndeffo-Mbah; Alison Galvani; Bruce Y Lee
Journal:  PLoS Negl Trop Dis       Date:  2018-11-05

5.  Does the political will exist to bring quality-assured and affordable drugs to low- and middle-income countries?

Authors:  Eduard J Beck; Sundhiya Mandalia; Boniface DongmoNguimfack; Eloan Pinheiro; Ellen 't Hoen; Pascale Boulet; John Stover; Aashta Gupta; Sandeep Juneja; Vincent Habiyambere; Peter Ghys; Cesar Nunez
Journal:  Glob Health Action       Date:  2019       Impact factor: 2.640

6.  Home improvement and system-based health promotion for sustainable prevention of Chagas disease: A qualitative study.

Authors:  Claudia Nieto-Sanchez; Benjamin R Bates; Darwin Guerrero; Sylvia Jimenez; Esteban G Baus; Koen Peeters Grietens; Mario J Grijalva
Journal:  PLoS Negl Trop Dis       Date:  2019-06-13

7.  The potential economic value of a therapeutic Chagas disease vaccine for pregnant women to prevent congenital transmission.

Authors:  Sarah M Bartsch; Owen J Stokes-Cawley; Pierre Buekens; Lindsey Asti; Maria Elena Bottazzi; Ulrich Strych; Patrick T Wedlock; Elizabeth A Mitgang; Sheba Meymandi; Jorge Abelardo Falcon-Lezama; Peter J Hotez; Bruce Y Lee
Journal:  Vaccine       Date:  2020-03-12       Impact factor: 3.641

Review 8.  Therapeutic Interventions for Countering Leishmaniasis and Chagas's Disease: From Traditional Sources to Nanotechnological Systems.

Authors:  Eliana B Souto; João Dias-Ferreira; Sara A Craveiro; Patrícia Severino; Elena Sanchez-Lopez; Maria L Garcia; Amélia M Silva; Selma B Souto; Sheefali Mahant
Journal:  Pathogens       Date:  2019-08-01

Review 9.  Implications of asymptomatic infection for the natural history of selected parasitic tropical diseases.

Authors:  Jorge Alvar; Fabiana Alves; Bruno Bucheton; Louise Burrows; Philippe Büscher; Eugenia Carrillo; Ingrid Felger; Marc P Hübner; Javier Moreno; Maria-Jesus Pinazo; Isabela Ribeiro; Sergio Sosa-Estani; Sabine Specht; Antoine Tarral; Nathalie Strub Wourgaft; Graeme Bilbe
Journal:  Semin Immunopathol       Date:  2020-03-18       Impact factor: 9.623

10.  Tolerance to nifurtimox and benznidazole in adult patients with chronic Chagas' disease.

Authors:  Yves Jackson; Baptiste Wyssa; François Chappuis
Journal:  J Antimicrob Chemother       Date:  2020-03-01       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.